Last reviewed · How we verify
Human Papillomavirus
Human Papillomavirus (HPV) vaccines stimulate the immune system to produce antibodies against specific HPV types, preventing infection and associated cancers.
Human Papillomavirus (HPV) vaccines stimulate the immune system to produce antibodies against specific HPV types, preventing infection and associated cancers. Used for Prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18, Prevention of anal, oropharyngeal, and other HPV-related cancers, Prevention of genital warts caused by HPV types 6 and 11 (in multivalent formulations).
At a glance
| Generic name | Human Papillomavirus |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Prophylactic vaccine |
| Target | Human Papillomavirus capsid protein (L1) |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
HPV vaccines contain virus-like particles (VLPs) derived from the major capsid protein of HPV, which trigger both humoral and cellular immune responses. These responses generate protective antibodies that prevent viral infection of epithelial cells, thereby reducing the risk of HPV-related cancers including cervical, anal, oropharyngeal, and other malignancies. The vaccine is typically administered as a series of intramuscular injections in adolescents and young adults.
Approved indications
- Prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18
- Prevention of anal, oropharyngeal, and other HPV-related cancers
- Prevention of genital warts caused by HPV types 6 and 11 (in multivalent formulations)
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Headache
- Myalgia
- Nausea
Key clinical trials
- The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants (PHASE2)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) (NA)
- Merck IIT: RRP Pembro and Lenvatinib (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Papillomavirus CI brief — competitive landscape report
- Human Papillomavirus updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI